



**ASX Announcement**  
**Invitrocue Limited (ASX:IVQ)**

## **Invitrocue's Onco-PDO™ Cancer Test Successfully Registered for CE Mark**

### **Highlights**

- **Invitrocue has successfully registered CE Mark for its Onco-PDO™ Cancer Test**
- **The CE Mark allows the test to be sold in the European Economic Region**

21 April 2020: Innovative life sciences company **Invitrocue Limited (ASX: IVQ)**, (**'Invitrocue' or 'the Company'**) is pleased to announce that it has completed CE Mark registration for its Onco-PDO™ test and has notified the German Institute for Medical Documentation and Information (DIMDI) of the registration.

The CE mark requires a declaration of conformity by the manufacturer that the product meets EU standards for health, safety, and environmental protection, and allows the product to be sold in any part the European Economic Area. Invitrocue's Onco-PDO™ has met the provisions of Directive 98/97 EC Annex III for in-vitro diagnostic medical devices.

Onco-PDO™ will soon be commercially available to oncologists and patients across Europe, starting in Germany and subsequently in Spain, and other markets such as Brazil. Invitrocue Germany will also be seeking to list Onco-PDO™ under the German Healthcare reimbursement system in due course.

Whereas many cancer treatments today are "one-size-fits-all", Invitrocue's Onco-PDO™ test takes a personalised approach and allows physicians to prescribe the most appropriate treatment regime based on patient's cancer cell phenotypic resistance or response to specific chemotherapeutic drugs.

**Dr. Andreas Lindner, CEO of Invitrocue Germany, said:** "We are very pleased that Onco-PDO™ has successfully registered for the CE Mark, as Europe is a big market where we can offer our test. We are looking forward to helping doctors in the region make more informed decisions about the best treatment path for cancer patients."

This announcement has been approved and authorised by the Board of Invitrocue Limited.

**For further information, please contact:**

**Martin D. Bach**  
VP Operations  
M: +65 6460 0497  
E: [martind.bach@invitrocue.com](mailto:martind.bach@invitrocue.com)

**[www.invitrocue.com](http://www.invitrocue.com)**



### **About Invitrocue (ASX:IVQ)**

Invitrocue Limited (ASX:IVQ) is an innovative life sciences company that specialises in developing ground-breaking 3D cell-based models derived from liver and tumour tissues.

Headquartered in Singapore and with operations in Australia, China, Hong Kong and Germany, Invitrocue's Onco-PDO technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support personalised clinical decisions.

By enabling assessments of the best ways for drugs to be developed, Invitrocue creates better, faster and more affordable disease treatments, that work towards the company's goal of creating a healthier society.

To learn more, please visit: [www.invitrocue.com](http://www.invitrocue.com)